Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Are Uterine Manipulators Harmful in Minimally Invasive Endometrial Cancer Surgery? A Retrospective Cohort Study.

Cancers·2025
Same author

The Challenges of Contemporary Atherosclerotic Cardiovascular Disease Management.

The Canadian journal of cardiology·2024
Same author

Not for the Faint of Heart: Environmental Influences on Cardiovascular Health.

The Canadian journal of cardiology·2023
Same author

Toward a Cardio-Environmental Risk Model: Environmental Determinants of Cardiovascular Disease.

The Canadian journal of cardiology·2023
Same author

Trends in major adverse cardiac events and healthcare utilization during the COVID-19 pandemic in Alberta, Canada.

CJC open·2023
Same author

Circulating adrenal 11-oxygenated androgens are associated with clinical outcome in endometrial cancer.

Frontiers in endocrinology·2023

相关实验视频

Updated: May 5, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

通过皮肤冠状动脉干预后AGI-1067和普鲁科尔的作用.

Jean-Claude Tardif1, Jean Grégoire, Leonard Schwartz

  • 1Montreal Heart Institute, Montreal, Canada. tardifjc@icm.umontreal.ca

Circulation
|February 5, 2003
PubMed
概括
此摘要是机器生成的。

通过皮肤冠状动脉干预 (PCI) 后,AGI-1067和普鲁科尔可降低静脉缩. 通过不延长QTc间隔,AGI-1067提供了一个比普鲁科尔更安全的替代品.

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.0K

相关实验视频

Last Updated: May 5, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.0K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学 是一个学科.
  • 医疗器械 医疗器械

背景情况:

  • AGI-1067是一种经过修改的试剂,具有类似的抗氧化功效,但具有不同的药理学.
  • 在心血管研究中,Probucol被用作正控.
  • 在PCI后的残留症是一个显著的临床问题.

研究的目的:

  • 评估AGI-1067在PCI后减少缩后的疗效.
  • 使用静脉内超声波 (IVUS) 将AGI-1067与安慰剂和试验剂进行比较.
  • 评估AGI-1067的安全概况,特别是QTc间隔变化.

主要方法:

  • 一个多中心的随机试验,涉及305名接受PCI的患者.
  • 患者在PCI前2周和PCI后4周接受安慰剂,普罗布科尔或不同剂量的AGI-1067.
  • 血管内超声波 (IVUS) 用于评估基线和6个月后的光线区域.

主要成果:

  • 与安慰剂 (P<0.05) 相比,AGI-1067 (280 mg) 和普鲁科尔显著降低了静止症 (P<0.05).
  • 观察到AGI-1067的剂量反应关系 (P=0.02).
  • AGI-1067没有显示显著的QTc间隔延长,与probucol不同 (P=0.02).

结论:

  • AGI-1067有效地减少PCI后的复缩,类似于probucol.
  • AGI-1067在QTc间隔延长方面表现出卓越的安全性.
  • AGI-1067可能对动脉样硬化有直接的有益影响,改善光线尺寸.